Investigation of Factors Affecting the Formation of Secondary Non-Traumatic Fractures Due to Mineral Bone Disorder in Hemodialysis Patients: A Single-Center Experience
Non-traumatic Fracture in Hemodialysis
Abstract views: 35
/ 
PDF downloads: 20
DOI:
https://doi.org/10.5281/zenodo.16733918Keywords:
Hemodialysis Units, Hospital, Chronic Kidney Disease-Mineral and Bone Disorders, Non-Traumatic FractureAbstract
Background: In our study, we aimed to determine whether demographic data and biochemical parameters of patients undergoing hemodialysis influence the prediction of secondary non-traumatic fractures due to mineral bone disorder caused by chronic kidney disease.
Methods: This cross-sectional study was conducted by retrospectively scanning the records of patients aged 18 years and older who had undergone hemodialysis for at least six months at our hospital’s hemodialysis unit between 2017 and 2022. A total of 272 patients meeting the inclusion criteria were examined through hospital records.
Results: Of the 272 patients included in the study, 57.7% were males, and the median age was 65 years. Non-traumatic fractures were detected in 32 (11.8%) patients. Non-traumatic fractures were significantly more common in female patients compared to males (18.3% vs. 7%; p=0.008). Eight patients had undergone parathyroidectomy, and among them, non-traumatic fractures were significantly more frequent compared to those who had not undergone the procedure (50% vs. 10.6%; p=0.008). Patients using steroids had significantly more non-traumatic fractures compared to non-users (26.9% vs. 10.2%; p=0.021). The duration of dialysis was significantly longer in patients with non-traumatic fractures compared to those without (60.5 months [7 - 324] vs. 39.5 months [7 - 330]; p=0.017). The risk of non-traumatic fractures was found to be 3.66 times higher in women, 4.17 times higher in steroid users, and increased by 0.7% with each additional month of dialysis.
Conclusion: This study investigated factors influencing non-traumatic fractures associated with mineral bone disorder in hemodialysis patients. Female gender, steroid use, parathyroidectomy, and dialysis duration were found to increase the risk of fractures. No significant association was found between fractures and other laboratory parameters or medications used by patients to regulate bone mineral metabolism.
References
Scott IA, Scuffham P, Gupta D, Harch TM, Borchi J, Richards B. Going digital: a narrative overview of the effects, quality and utility of mobile apps in chronic disease self-management. Aust Health Rev. 2020;44(1):62-82. doi:10.1071/AH18064
Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019;322(13):1294-1304. doi:10.1001/jama.2019.14745
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-S130. doi:10.1038/ki.2009.188
Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953. doi:10.1038/sj.ki.5000414
Seck SM, Dahaba M, Ka EF, Cisse MM, Gueye S, Tal AO. Mineral and bone disease in black african hemodialysis patients: a report from senegal. Nephrourol Mon. 2012;4(4):613-616. doi:10.5812/numonthly.4225
Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004;43(3):558-565. doi:10.1053/j.ajkd.2003.12.003
Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1-12. doi:10.1053/ajkd.2003.50007
Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl. 2005;(94):S14-S18. doi:10.1111/j.1523-1755.2005.09403.x
Thomson P, Stirling C, Traynor J, Morris S, Mactier R. A prospective observational study of catheter-related bacteraemia and thrombosis in a haemodialysis cohort: univariate and multivariate analyses of risk association. Nephrol Dial Transplant. 2010;25(5):1596-1604. doi:10.1093/ndt/gfp667
Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913-921. doi:10.2215/CJN.06040710
Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003;41(5):997-1007. doi:10.1016/s0272-6386(03)00197-5
Cavalier E, Delanaye P, Moranne O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis. 2013;61(5):847-848. doi:10.1053/j.ajkd.2012.12.013
Alexander AJ, Jahangir D, Lazarus M, Sprague SM. Imaging in Chronic Kidney Disease-Metabolic Bone Disease. Semin Dial. 2017;30(4):361-368. doi:10.1111/sdi.12598
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001
Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70(7):1358-1366. doi:10.1038/sj.ki.5001754
Matias PJ, Laranjinha I, Azevedo A, et al. Bone fracture risk factors in prevalent hemodialysis patients. J Bone Miner Metab. 2020;38(2):205-212. doi:10.1007/s00774-019-01041-9
Stehman-Breen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(5):2200-2205. doi:10.1111/j.1523-1755.2000.00394.x
Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333(3):166-174. doi:10.1056/NEJM199507203330307
Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol. 2007;18(8):2401-2407. doi:10.1681/ASN.2007010022
Isaksson E, Ivarsson K, Akaberi S, et al. The Effect of Parathyroidectomy on Risk of Hip Fracture in Secondary Hyperparathyroidism. World J Surg. 2017;41(9):2304-2311. doi:10.1007/s00268-017-4000-0
Ishani A, Liu J, Wetmore JB, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10(1):90-97. doi:10.2215/CJN.03520414
Tanaka I. Glucocorticoid and bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis [Article in Japanese]. Clin Calcium. 2014 Sep;24(9):1371 1378.
Wakasugi M, Kazama JJ, Kikuchi K, et al. Hemodialysis Product and Hip Fracture in Hemodialysis Patients: A Nationwide Cohort Study in Japan. Ther Apher Dial. 2019;23(6):507-517. doi:10.1111/1744-9987.12807
Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(1):396-399. doi:10.1046/j.1523-1755.2000.00178.x
Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16(3):800-807. doi:10.1681/ASN.2004060512
Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516-1525. doi:10.1056/NEJMoa031633
Moe SM, Abdalla S, Chertow GM, et al. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015;26(6):1466-1475. doi:10.1681/ASN.2014040414
Ferreira A, Frazão JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19(2):405-412. doi:10.1681/ASN.2006101089
Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;8(8):CD006023. Published 2018 Aug 22. doi:10.1002/14651858.CD006023.pub3
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Özdem Kavraz Tomar, Haldun Öner, Tülin Akagün , Muhammed Aydın
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a 